Literature DB >> 6487375

Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717.

A L Jackman, G A Taylor, A H Calvert, K R Harrap.   

Abstract

CB3717 (N-(4-(N-((2-amino-4- hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino ) benzoyl)-L-glutamic acid) is an antitumour agent that inhibits thymidylate synthetase (TS). A dose-dependent fall in plasma thymidine (dThd) (1.43 microM to 0.47 microM) occurred in non-tumour-bearing mice following the administration of CB3717. Further, in mice carrying the L1210/CBRI tumour, the drug's antitumour properties were ablated by co-administration of dThd, an effect consistent with TS being the cytotoxic locus. In vitro studies of protection by dThd against CB3717 cytotoxicity were carried out in an attempt to quantify this reversal. The metabolism of [14C]-dThd was measured in cultures of L1210 cells (10(4)/ml) exposed to a completely cytotoxic dose of CB3717 (50 microM). The cytotoxicity of the drug was only expressed when the dThd concentration (0.5-2 microM) had fallen to less than 0.1 microM in the media. This reduction was due to: (1) dThd incorporation into DNA, (2) catabolism of dThd to thymine. By reducing the initial cell concentration to 10(3)/ml the depletion of dThd was substantially reduced and consequently cells continued to grow for a longer period. The critical concentration of dThd, below which growth in the presence of CB3717 could not be supported was estimated to be between 0.026 and 0.1 microM. Thus even the minimum level of dThd achieved in vivo was still in excess of that required for protection from CB3717 toxicity in vitro. There was a small accumulation of deoxyuridine (dUrd) (approximately 2-fold) in mouse plasma 24 hr after completion of a 5-day course of CB3717 (200 mg/kg) but in vitro studies demonstrated that this was unlikely to modulate CB3717 toxicity in the presence of dThd. We caution against the use of rodent tumour models (or human tumour xenografts) for antitumour or toxicity testing of compounds designed to inhibit the de novo synthesis of thymidylate; they may be misleading because the high dThd levels found in these animals compared with man may mask the cytotoxic effects of these drugs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6487375     DOI: 10.1016/0006-2952(84)90089-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

Review 1.  Clinical and preclinical pharmacokinetics of raltitrexed.

Authors:  S J Clarke; P J Beale; L P Rivory
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 2.  Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.

Authors:  A L Jackman; F T Boyle; K R Harrap
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.

Authors:  Garry H Schwartz; Christopher B Jones; Mitchell Garrison; Amita Patnaik; Chris Takimoto; Heather McCreery; Michael Skinner; Anthony W Tolcher; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

Review 4.  The role of DNA synthesis imaging in cancer in the era of targeted therapeutics.

Authors:  Sridhar Nimmagadda; Anthony F Shields
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

5.  Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.

Authors:  B Mitrovski; J Pressacco; S Mandelbaum; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations.

Authors:  S D Banks; K A Waters; L L Barrett; S Dickerson; W Pendergast; G K Smith
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Organ culture as a model for investigating the effects of antimetabolites and nucleoside transport inhibitors on rodent colonic mucosa.

Authors:  M Moorghen; P Ince; K J Finney; A J Watson; A L Harris
Journal:  In Vitro Cell Dev Biol       Date:  1991-11

8.  Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.

Authors:  Kawai Yau; Patricia Price; Radhakrishma G Pillai; Eric Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-28       Impact factor: 9.236

Review 9.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651

10.  Thiothymidine plus low-dose UVA kills hyperproliferative human skin cells independently of their human papilloma virus status.

Authors:  Olivier Reelfs; Yao-Zhong Xu; Andrew Massey; Peter Karran; Alan Storey
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.